120 related articles for article (PubMed ID: 22127310)
1. Evaluation of prognostic factors in AML. Preface.
Rowe JM
Best Pract Res Clin Haematol; 2011 Dec; 24(4):485-8. PubMed ID: 22127310
[No Abstract] [Full Text] [Related]
2. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
[TBL] [Abstract][Full Text] [Related]
3. New agents: great expectations not realized.
Lancet JE
Best Pract Res Clin Haematol; 2013 Sep; 26(3):269-74. PubMed ID: 24309529
[TBL] [Abstract][Full Text] [Related]
4. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
Bergua JM; Montesinos P; Martinez-Cuadrón D; Fernández-Abellán P; Serrano J; Sayas MJ; Prieto-Fernandez J; García R; García-Huerta AJ; Barrios M; Benavente C; Pérez-Encinas M; Simiele A; Rodríguez-Macias G; Herrera-Puente P; Rodríguez-Veiga R; Martínez-Sánchez MP; Amador-Barciela ML; Riaza-Grau R; Sanz MA;
Br J Haematol; 2016 Sep; 174(5):700-10. PubMed ID: 27118319
[TBL] [Abstract][Full Text] [Related]
5. Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Tallman M
Clin Adv Hematol Oncol; 2008 Nov; 6(11):3-5. PubMed ID: 19205108
[No Abstract] [Full Text] [Related]
6. Overall survival in acute myeloid leukaemia patients with and without internal tandem duplication.
Shahab S; Qadar Z; Nadeem M; Zahid D; Ansari S; Farzana T; Taj M; Borhany M; Ahmed N; Shamsi TS
Asian Pac J Cancer Prev; 2015; 16(1):393. PubMed ID: 25640387
[No Abstract] [Full Text] [Related]
7. Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.
Prebet T; Etienne A; Devillier R; Romeo E; Charbonnier A; D'incan E; Esterni B; Arnoulet C; Blaise D; Vey N
Cancer; 2011 Mar; 117(5):974-81. PubMed ID: 20957721
[TBL] [Abstract][Full Text] [Related]
8. Coexistence of BCR/ABL1 p190 transcript and CEBPA double mutations in de novo acute myeloid leukemia.
Zhang X; Guo X
Leuk Lymphoma; 2019 Nov; 60(11):2844-2846. PubMed ID: 31050567
[No Abstract] [Full Text] [Related]
9. Mobilization-driven postconsolidation therapy in elderly patients with acute myeloid leukemia: feasibility and efficacy of autologous stem cell transplantation versus low-dose gemtuzumab ozogamicin.
Capelli D; Chiarucci M; Poloni A; Saraceni F; Mancini G; Trappolini S; Troiani E; Montanari M; Scortechini I; Offidani M; Rupoli S; Scortechini AR; Gini G; Discepoli G; Leoni P; Olivieri A
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1399-406. PubMed ID: 24880020
[TBL] [Abstract][Full Text] [Related]
10. Are immunoconjugates approaching "standard of care" in AML?
Estey E
Best Pract Res Clin Haematol; 2013 Sep; 26(3):261-8. PubMed ID: 24309528
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
[TBL] [Abstract][Full Text] [Related]
12. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction.
Haydu JE; Flamand Y; Vedula RS; Versluis J; Charles A; Copson KM; Stone RM; DeAngelo DJ; Neuberg D; Lindsley RC; Luskin MR
Am J Hematol; 2021 Jul; 96(7):E259-E262. PubMed ID: 33837971
[No Abstract] [Full Text] [Related]
14. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents.
Tallman MS
Hematology Am Soc Hematol Educ Program; 2005; ():143-50. PubMed ID: 16304372
[TBL] [Abstract][Full Text] [Related]
15. Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?
Yang J; Schiffer CA
Expert Rev Hematol; 2012 Aug; 5(4):395-407. PubMed ID: 22992234
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic factors of acute myeloid leukemia].
Inokuchi K
Nihon Rinsho; 2012 Apr; 70 Suppl 2():389-93. PubMed ID: 23133988
[No Abstract] [Full Text] [Related]
17. Treatment of AML: resurrection for gemtuzumab ozogamicin?
Estey E
Lancet; 2012 Apr; 379(9825):1468-9. PubMed ID: 22482941
[No Abstract] [Full Text] [Related]
18. Is a nadir bone marrow required and, if so, what to do with residual disease?
Luger SM
Best Pract Res Clin Haematol; 2011 Dec; 24(4):527-32. PubMed ID: 22127316
[TBL] [Abstract][Full Text] [Related]
19. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
Paubelle E; Ducastelle-Leprêtre S; Labussière-Wallet H; Nicolini FE; Barraco F; Plesa A; Salles G; Wattel E; Thomas X
Ann Hematol; 2017 Mar; 96(3):363-371. PubMed ID: 28011984
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
